Lymphoma Tumor Board

January 5, 2018

Etiology

Etiology - Hodgkin Lymphoma

Infectious agents	 EBV, may be involved in the pathogenesis. In as many as 50% of cases, the tumor cells are EBV-positive. Patients with HIV infection have a higher incidence of Hodgkin lymphoma compared with the population without HIV infection.
Genetic predisposition	 Approximately 1% of patients with Hodgkin lymphoma have a family history of the disease.
UV radiation exposure	 May have a protective effect against lymphomagenesis through mechanisms that may be independent of vitamin D

Source: http://emedicine.medscape.com/article/201886-overview#aw2aab6b2b3




Subtypes of <u>Classical</u> Hodgkin Lymphoma (cHL)*

- Nodular sclerosing HL
 - Most common subtype
 - Composed of large tumor nodules
 - Nodules show scattered lacunar classical Reed Sternberg (RS) cells that are reactive
- Mixed-cellularity subtype
 - Common subtype
 - Composed of numerous classic RS cells with inflammatory cells
 - Frequently associated with EBV infection
 - Can be confused with "cellular" phase of nodular sclerosing CHL.
- Lymphocyte-rich
 - Rare subtype
 - Has most favorable prognosis
- Lymphocyte-depleted
 - Rare subtype
 - Composed of large numbers of pleomorphic RS cells with intermixed with reactive lymphocytes, which can be confused with DLBCL
- *~5% of patients have "nodular lymphocyte predominant Hodgkin lymphoma"

Staging of Hodgkin Lymphoma (HL)

- Stage I ٠
 - Involvement of single lymph node region
 - Typically, cervical nodes or single extralymphatic site (stage IE)
- Stage II ٠
 - Involvement of two or more lymph node regions on same side of diaphragm
 - One lymph node region and a contiguous extralymphatic site (IIE)
- Stage III
 - Involvement of two or more lymph node regions on both sides of the diaphragm
 - Can include spleen (IIIS) and/or limited contiguous extralymphatic organ sites (IIIE, IIIES)
- Stage IV
 - Disseminated involvement of one or more extralymphatic organs



lymphoma

lymphoma


lymphoma

lymphoma

- Uncommon entity in contrast to classical Hodgkin lymphoma (cHL)
 - Considered indolent
- Represent ~5% of Hodgkin lymphoma
- Universally expresses CD20 which is a hallmark of the disease
 - Does not express CD15 or CD30
- BCL6 gene rearrangements have been frequently observed
- Majority present with early-stage disease
- Unlike cHL, late relapses may occur, as well as propensity to transform to an aggressive B-cell NHL
- Deaths caused by NLPHL are rare
 - Morbidity is caused by secondary malignancies


(NLPHL) – Pathology

- The term "Popcorn cells" has been used due to the number of increased nucleoli and and microscopic appearance
- One mixture of LP cells and small B cells is required for a diagnosis of NLPHL
- LP cells are usually seen in the background of B-cell-rich lymphoid follicles associated with follicular dendritic cell meshworks
- Unlike Reed-Sternberg cells in classical HL (cHL), LP cells lack expression of CD15, CD30, and EBV
- Typical B-cell phenotype is seen cells express CD20, CD45, CD75 and often J-chain
- Epithelial membrane antigen is present in ~50% of cases
- Progressive transformation of germinal centers (PTGCs) can be mistaken for NLPHL




(arrows: CD20, 200x). **b**. More enhanced CD20 expression in "LP type" DLBCL (same lymph node and same section, CD20, 200x). **c**. Weak CD79a expression in LP cells of NLPHL (arrows: CD79a, 200x). **d**. More enhanced CD79a expression in "LP type" DLBCL (same lymph node, CD79a, 200x). **e**. Weak CD19 expression in LP cells of NLPHL (arrows: CD19, 200x). **f**. More enhanced CD19 expression in "LP type" DLBCL (same lymph node, CD19, 200x).






















Table 3. NCCN and ESMO guidelines for NLPHL

				Stage		
Guideline	IA, no risk factors ⁴⁰	IB	IIA	IIB	III/IV A	III/IV B
NCCN guidelines, version 2.2013 ³⁹ (all category 2A unless otherwise indicated)	Observe* or ISRT	CHT ± rituximab ± ISRT	Observe or ISRT	CHT ± rituximab ± ISRT	CHT \pm rituximab \pm RT or observation† or local RT‡	CHT ± rituximab ± RT
ESMO ⁴⁰	IFRT	CHT ± IFRT	$\text{CHT} \pm \text{IFRT}$	CHT ± IFRT	СНТ	CHT

CHT, chemotherapy (for details see reference).

*Option for completely excised solitary lymph node

†Category 2B

‡Palliation only



Risk factors for transformation and recurrent NLPHL in advanced-stage NLPHL





Table 2. Outcome of patients with advanced-stage NLPHL compared with matched controls with advanced-stage CHL

			Survival (%)		
	HL subtype	5-Year	10-Year	15-Year	P
HL-FFTF	NLPHL	82	75	52	.610
	CHL	78	73	73	
TTP	NLPHL	72	63	44	.040
	CHL	78	73	73	
OS	NLPHL	89	83.5	74	.826
	CHL	91	81	68	
TTT	NLPHL	12	15	24	.00018
	CHL	0	0	0	

TTT, time to transformation.

TTP in NLPHL vs CHL



Overall Survival in NLPHL vs CHL






Table 3. Cause of death in NLPHL and CHL patients


Cause of death	NLPHL ((n = 10)	CHL (n = 17)		
	No.	%	No.	%	
HL	1	10	8	47	
Aggressive NHL	4	40	0		
Secondary cancers	1	10	3	18	
Cardiac	4	40	6	35	

TTP in patients treated with ABVD by splenic involvement at diagnosis of NLPHL



Kaplan-Meier estimates for progression-free survival








Julien Lazarovici et al. Haematologica 2015;100:1579-1586

©2015 by Ferrata Storti Foundation


Progression-free survival by management at diagnosis





Julien Lazarovici et al. <u>Haematologica</u> 2015;100:1579-1586

Progression-free survival of 58 patients after complete surgical resection



Superior of the European Hematology Association Published by the Ferrata Stort Foundation

©2015 by Ferrata Storti Foundation

Julien Lazarovici et al. <u>Haematologica</u> 2015;100:1579-1586

Management of patients at diagnosis

Table 2.

Management of patients at diagnosis and first

relapse/progression.

Management of patients at diagnosis	Stage I-II	Stage III-IV		Total
Watchful waiting	104	10		114 (36.3%)
Radiotherapy	62	1		63 (20.1%)
Rituximab alone	24	4		28 (8.996)
Chemotherapy or immuno-chemotherapy ²	36	32		68 (21.796)
Combined modality treatment ²	33	7		40 (12.796)
Radiotherapy plus rituximab	0	1		1 (0.396)
				7
Management at first relause/progression				
Management at first relapse/progression	Stage I-II	Stage III-IV	Stage unknown	Total
	Stage I-II 13	Stage III-IV 4	Stage unknown	Total 19 (17.096)
Watchful waiting		Stage III-IV 4 0	Stage unknown 2 8	
Watchful waiting Radiotherapy	13	Stage III-IV 4 0 3	Stage unknown 2 8 3	19 (17.096) 27 (24.196)
Watchful waiting Radiotherapy Rituximab alone	13	Stage III-IV 4 0 3 19	Stage umknown 2 8 3 7	19 (17.096) 27 (24.196) 19 (17.096)
Watchful waiting Radiotherapy Rituximab alone Themotherapy or immuno-chemotherapy*	13	Stage III-IV 4 0 3 19 1	Stage unknown 2 8 3 7 2	19 (17.0%) 27 (24.1%) 19 (17.0%) 37 (33.0%)
Management at first relayse/progression Watchful waiting Radiotherapy Rituximab alone Chemotherapy or immuno-chemotherapy ² Combined modality treatment ¹ Radiotherapy plus rituximab	13	Stage III-IV 4 0 3 19 1 0	Stage unknown 2 8 3 7 2 1	19 (17.096) 27 (24.196) 19 (17.096)

Batiotherapy does: 43 patients (68.2%) received 20 to 36 Qx T patients (11.1%) 38 to 40 Qx 2 patients (3.2%) 20 Qx 3 patients (4.8%) 4 Gy The dose of radiotherapy uses unknown (rs. 6 patients (12.6%) RNR-Received (4.8%) 4 Gy The advantage (4.8%) 4 Gy The dose of radiotherapy (13.8%) 4 Gy The dose of radiotherapy uses unknown (rs. 6 patients (12.6%) RNR-Received (4.9%) Chemotherapy (61), industing ARVD or ARVDbite regimens (76), BBACOPP (1), CHOP (r), CHOP or CHOPAke regimens (18, all beated without radiotherapy), CVP (T), other regimens (2), unspecified (4.9%) Chemotherapy and (13), chemotherapy + Rucinab (31), Chimotherapy (18, 2%), DRAP or DBA-cabopitatin (2), DEC (1), CVP (1), other regimens (2), unspecified (1), ARVD: downabics, BACOPP (1), other regimens (2), unspecified (1), ARVD: downabics, BACOPP (1), other regimens (2), unspecified (1), ARVD: downabics, BACOPP (1), other regimens (2), unspecified (1), ARVD: downabics, DBA-cabopitatin (2), DEC (1), CVP (1), other regimens (2), unspecified (1), ARVD: downabics, DBA-cabopitatin (2), DEC (1), CVP (1), other regimens (2), unspecified (1), ARVD: downabics, DBA-cabopitatin (2), DEC (1), CVP (1), other regimens (2), unspecified (1), ARVD: downabics, DBA-cabopitatin (2), DEC (1), CVP (1), other regimens (2), Unspecified (1), ARVD: downabics, DBA-cabopitatin (2), DEC (1), CVP (1), other regimens (2), unspecified (1), ARVD: downabics, DBA-cabopitatin (2), DEC (1), CVP (1), other regimens (2), unspecified (1), ARVD: downabics, DBA-cabopitatin (2), DEC (1), CVP (1), Other (2), BACOPP (1), Other (2), BACOPP (1), CHOP (1), ARVD: downabics, DBA-cabopitatin (2), DEC (1), CVP (1), Other (2), DEC (1), CVP (1), Other (2), BACOPP (1), CHOP (1), C

Table 3.

Response to initial and second-line treatments.

Response to initial treatment (evaluable patients, n=200)					
	CR/CRu	PR	SD	Progression	Unknown
All	166	10	2	5	17
Radiotherapy	54	1	1	1	6
Rituximab alone	24	3	0	0	1
Chemotherapy or immuno-chemotherapy	55	5	1	2	5
Combined modality treatment	32	1	0	2	5
Radiotherapy plus rituximab	1	0	0	0	0
Response to second-line treatment (evaluable patients, n=92)					
	CR/CRu	PR	SD	Progression	Unknown
All	66	10	2	2	12
Radiotherapy	19	3	1	0	4
Rituximab alone	12	5	0	0	2
Chemotherapy or immuno-chemotherapy	27	2	1	2	5
Combined modality treatment	6	0	0	0	1
Radiotherapy plus rituximab	2	0	0	0	0

Risk of progression in NLPHL patients

Table 4.

Risk of progression after initial treatment.

	Hazard ratio	95% CI	P
Radiotherapy	0.345	0.196-0.610	0.0002
Rituximab alone	0.629	0.283-1.399	0.256
Chemotherapy or immuno-chemotherapy	0.476	0.266-0.855	0.0129
Combined modality treatment	0.292	0.148-0.577	0.0004

Hazard ratios are calculated with watchful waiting taken as a reference.

References

- Xing, K. H., Connors, J. M., Lai, A., Al-Mansour, M., Sehn, L. H., Villa, D., Klasa, R., Shenkier, T., Gascoyne, R. D., Skinnider, B., & Savage, K. J. (2014). Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. Blood, 123(23), 3567-3573. Accessed December 07, 2017. <u>https://doi.org/10.1182/blood-2013-12-541078</u>.
- Hartmann, etal.BMCCancer 2014, 14332, http://www.biomedcentral.com/1471-2407/14/332
- <u>https://en.wikipedia.org/wiki/Nodular_lymphocyte_predominant_Hodgkin's_lymphoma</u>
- <u>https://imagebank.hematology.org/image/60430/nodular-lymphocyte-predominant-hodgkin-lymphoma-1?type=upload</u>
- Advani, R. H., & Hoppe, R. T. (2013). How I treat nodular lymphocyte predominant Hodgkin lymphoma. Blood, 122(26), 4182-4188. Accessed December 06, 2017. <u>https://doi.org/10.1182/blood-2013-07-453241</u>.
- <u>https://www.verywell.com/hodgkins-lymphoma-4013744</u>